LIVN
LivaNova PLC
LIVN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over LIVN overall, supported by stronger fundamentals and stronger modeled upside.
LIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
LIVN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LIVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $90.20 | — |
| Cheap | 29x | $87.18 | -3.3% |
| Current | 30x | $90.20 | — |
| Fair | 112x | $337 | +274% |
| Expensive | 769x | $2,314 | +2465% |
Historical ranges are pointers, not guarantees.
LIVN's PE is in its cheap range at 30x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over LIVN in the historical PE scenario, which offers more potential upside but is not a forecast.
LIVN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LIVN, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over LIVN on the outlook, with more favorable profitability expectations.
LIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.53 | +50% |
| Q3 2026 | $3.01 | +$6.99 |
| Q2 2026 | $3.39 | +$7.26 |
| Q1 2026 | $1.96 | +$6.03 |
| Q4 2025 | -$4.45 | -484% |
| Q3 2025 | -$3.98 | -1048% |
| Q2 2025 | -$3.87 | -$3.55 |
| Q1 2025 | -$4.07 | -$3.47 |
| Q4 2024 | $1.16 | +262% |
LIVN has returned to profit: it earned $3.01 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
LIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $393.1M | +9.9% |
| Q2 2026 | $390.6M | +11% |
| Q1 2026 | $362.3M | +14% |
| Q4 2025 | $360.9M | +12% |
| Q3 2025 | $357.8M | +12% |
| Q2 2025 | $352.5M | +11% |
| Q1 2025 | $316.9M | +7.4% |
| Q4 2024 | $321.8M | +3.8% |
LIVN's revenue has grown year over year for 16 quarters in a row: $393M last quarter, up 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | -7.9 points |
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 11% | -3.9 points |
| Q4 2025 | 12% | +0.3 points |
| Q3 2025 | 15% | +3.9 points |
| Q2 2025 | 15% | +2.8 points |
| Q1 2025 | 15% | +9.8 points |
| Q4 2024 | 12% | +40 points |
LIVN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LIVN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
LIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $42.9M | -31% |
| Q2 2026 | $35M | -27% |
| Q1 2026 | $926K | -93% |
| Q4 2025 | $50.2M | -27% |
| Q3 2025 | $62.2M | +89% |
| Q2 2025 | $47.8M | +53% |
| Q1 2025 | $13.2M | +268% |
| Q4 2024 | $68.3M | +66% |
LIVN still generates free cash flow, though less than at its 2024 peak: $129M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LIVN on cash flow, with more consistent year-over-year improvement.
LIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +1.1M shares |
| 1 year | +4% | +2.2M shares |
| 3 years | +6.3% | +3.4M shares |
| 5 years | +11% | +5.8M shares |
| Available history | +19% | +9M shares |
LIVN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LIVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.6x | Net Cash |
| Q4 2024 | 1.3x | Healthy |
LIVN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over LIVN on leverage, with a lower net debt burden relative to earnings.
LIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.0 | Neutral |
| Stochastic | 56.1 | Neutral |
LIVN's weekly RSI is 67 (neutral) and its Stochastic is 56 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LIVN PE vs Healthcare Sector
| Metric | LIVN | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 16% above |
| PE % | 19 | 29 | 10 pts below |
LIVN is trading at 30x earnings, a 16% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over LIVN on valuation relative to its sector.
LIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 12% above |
| 20 week MA | $80.3 | 12% above |
| 50 week MA | $72.3 | 25% above |
| 100 week MA | $59.7 | 51% above |
| 200 week MA | $55.5 | 62% above |
LIVN is in an uptrend: it's above all five of its weekly moving averages, and 62% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
LIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.4 | $67.4 | -11% |
| 2021 | $67.4 | $85.2 | +26% |
| 2022 | $85.2 | $53.7 | -37% |
| 2023 | $53.7 | $51.7 | -3.6% |
| 2024 | $51.7 | $46.6 | -10% |
| 2025 | $46.6 | $62.9 | +35% |
| 2026 YTD | $62.9 | $90.2 | +43% |
LIVN is up 43% so far in 2026, after finishing lower in four of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LIVN on returns for 2026, with the stronger performance.